Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by CytoSorbents Corporation on June 6, 2017. The filing details the outcomes of three specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
At the record date of April 12, 2017, there were 28,108,382 shares of Common Stock outstanding. A quorum was established with 20,518,756 shares represented. All three proposals were approved:
- Proposal 1 (Election of Directors): Five directors were elected to serve until the 2018 Annual Meeting. All nominees received majority support, though significant broker non-votes were recorded for each candidate.
- Proposal 2 (Incentive Plan): Stockholders approved the amendment and restatement of the 2014 Long-Term Incentive Plan. The vote was split, with 4,987,879 votes For, 2,627,462 Against, and 59,365 Abstain.
- Proposal 3 (Auditor Ratification): The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2017, was ratified with 20,082,051 votes For.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural results of the shareholder vote.
Investor Verification Checklist
- Verify the specific terms of the amended 2014 Long-Term Incentive Plan given the significant number of votes cast against the proposal.
- Confirm the tenure and responsibilities of the newly elected board members.
- Review the full proxy statement for details on the broker non-votes recorded during the director election.